Literature DB >> 1721257

In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.

R E Morris1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721257

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

1.  Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin.

Authors:  Jaime A Yáñez; M Laird Forrest; Yusuke Ohgami; Glen S Kwon; Neal M Davies
Journal:  Cancer Chemother Pharmacol       Date:  2007-03-29       Impact factor: 3.333

2.  Mutational biosynthesis of novel rapamycins by a strain of Streptomyces hygroscopicus NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase.

Authors:  L E Khaw; G A Böhm; S Metcalfe; J Staunton; P F Leadlay
Journal:  J Bacteriol       Date:  1998-02       Impact factor: 3.490

3.  Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy.

Authors:  Ha Na Woo; Hye Kyung Chung; Eun Jin Ju; Joohee Jung; Hye-Won Kang; Sa-Won Lee; Min-Hyo Seo; Jin Seong Lee; Jung Shin Lee; Heon Joo Park; Si Yeol Song; Seong-Yun Jeong; Eun Kyung Choi
Journal:  Int J Nanomedicine       Date:  2012-04-27

4.  Calcineurin inhibition enhances motor neuron survival following injury.

Authors:  Kelvin K W Hui; Nicole Liadis; Jennifer Robertson; Anish Kanungo; Jeffrey T Henderson
Journal:  J Cell Mol Med       Date:  2009-02-20       Impact factor: 5.310
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.